Impact of sequential (first- to third-generation) EGFR-TKI treatment on corrected QT interval in NSCLC patients

Authors: Tian Gan, Jindong Chen, Hao Wang, Conghui Shang, Siqi Xi, Zixu Fan, Ben He, Min Zhang, Liang Zhao

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: non-small cell lung cancer, epidermal growth factor receptor-tyrosine kinase inhibitor, corrected QT interval, risk factor, advanced lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1330165/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/55d2d51f4da2463bbf0ee2f3d05110ed